Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001137 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: December 6, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV Infections |
A compilation of outcomes of various antiretroviral therapies would be beneficial when evaluating which strategies are most effective in long-term treatment of HIV-1. Using data from present and recently completed studies, this study will collect information on therapies and their control of HIV infection and maintenance of durable suppression of HIV-1 replication.
No treatment is provided by this study, but patients will continue to receive highly active antiretroviral therapy (HAART) from other studies in which they are coenrolled. Blood and urine collection will occur at study entry and periodically throughout the study. Women may undergo pelvic exams and Pap smears. Portions of blood samples will be stored to evaluate genotypic/phenotypic susceptibility testing. Medical histories, physical exams, and questionnaires will be completed periodically.
Study Type : | Observational |
Actual Enrollment : | 5982 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) Protocol |
Study Start Date : | January 2000 |
Actual Primary Completion Date : | November 2013 |
Actual Study Completion Date : | November 2013 |

- Successive suppressed viral load measures [ Time Frame: Measured 144 weeks after randomization ]
- Genotypic or phenotypic resistance [ Time Frame: Measured at baseline and study completion ]
- Complications of HIV disease, including survival, HIV-related opportunistic infections, HIV-related non-opportunistic complications, adverse effects of antiretroviral therapies of grade three or greater [ Time Frame: Measured throughout ]
- Absolute number and percentage of CD4 and CD8 T cells [ Time Frame: Measured 144 weeks after randomization ]
- Absolute number and percentage of naive cells, including CD4, CD45RA, and CD62L cells [ Time Frame: Measured 144 weeks after randomization ]
- Absolute number and percentage of memory cells, including CD4, CD45RO+, and CD45RA- cells [ Time Frame: Measured 144 weeks after randomization ]
- Levels of immune activation markers, including CD8, CD38, and HLA-DR cells [ Time Frame: Measured 144 weeks after randomization ]
- HIV-1 latency or replication in tissue or cellular reservoirs [ Time Frame: Measured at baseline, Week 16, Week 48, and study completion ]
- Syncytium and non-syncytium inducing (SI/NSI) phenotype [ Time Frame: Measured at baseline, Week 16, Week 48, and study completion ]
- Metabolic and neurologic complications [ Time Frame: Measured at baseline, Week 16, Week 48, and study completion ]
- Immune responses to antigens such as cytomegalovirus (CMV), Myobacterium avium complex (MAC), Candida, and HIV [ Time Frame: Measured 144 weeks after randomization ]
- Plasma concentrations of antiretroviral medications other than nucleoside/tide reverse transcriptase inhibitors (NRTIs) [ Time Frame: Measured at baseline, Week 16, and study completion ]
- Effect of gender, use of hormonal therapies, presence or absence of menopause on short- and long-term virologic suppression, and pap smear abnormalities [ Time Frame: Measured at baseline, Week 48, and study completion ]
- Quality of life scores [ Time Frame: Measured at baseline, Week 48, and study completion ]
- Subject-reported patterns of adherence [ Time Frame: Measured at baseline, Week 48, and study completion ]
- Estimated inpatient, outpatient, and total costs [ Time Frame: Measured at study completion ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria
- HIV-1 infected
- Enrolled in an AIDS Clinical Trial Group (ACTG) parent study and has enrolled in this study on or before the Week 16 visit of the parent study, including the visit window of the parent study. More information on this criterion can be found in the protocol.
- Willing to provide consent for the release and use of clinical data from the parent study
- Life expectancy of at least 24 weeks
- Parent or guardian willing to provide informed consent, if applicable
Exclusion Criteria
- Active alcohol or drug abuse that may interfere with the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001137

Study Chair: | Constance A. Benson, MD | Division of Infectious Disease, Antiviral Research Center, University of California, San Diego | |
Study Chair: | Ann C. Collier, MD | University of Washington |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | AIDS Clinical Trials Group |
ClinicalTrials.gov Identifier: | NCT00001137 History of Changes |
Other Study ID Numbers: |
ACTG A5001 1U01AI068636 ( U.S. NIH Grant/Contract ) AACTG A5001 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | December 6, 2013 |
Last Verified: | December 2013 |
Keywords provided by AIDS Clinical Trials Group:
Treatment Experienced Treatment Naive Virus Replication AIDS-Related Opportunistic Infections HIV-1 Risk Factors Incidence |
RNA, Viral Anti-HIV Agents Viral Load Lipodystrophy Nervous System Cardiovascular System Neurologic Symptoms |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |